Posted on September 5, 2018 by Sitemaster
A media release issued on Tuesday this week by a usually highly respected medical center in the Los Angeles area is misleadingly entitled, “Hormone therapy can make prostate cancer worse, study finds”. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: androgen-resistant, androgen-sensitive, epigenetic, glutamate, neuroendocrine, transition | 6 Comments »
Posted on May 19, 2017 by Sitemaster
The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene.
… READ MORE …
Filed under: Drugs in development | Tagged: EMT, expression, miR-3622a, transition | Leave a comment »
Posted on November 30, 2012 by Sitemaster
The other day we reported on a study by Bensawy et al. supporting the idea that epithlial-to-mesenchymal transition or EMT might be an underlying mechanism driving prostate cancer metastasis. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk | Tagged: EMT, epithelial, mesenchymal, metastasis, transition, Twist1 | 2 Comments »
Posted on November 27, 2012 by Sitemaster
The spreading of prostate cancer cells from the prostate to distant sites in the body (“metastasis”) is a critical factor in why prostate cancers lead to patients’ deaths, … but we still don’t really know what triggers prostate cancer cells (or any other cancer cells for that matter) to metastasize. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: epithelial, mesenchymal, metastasis, progression, risk, transition, Twist, vimentin | 3 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 